31 results about "SH-SY5Y" patented technology

The invention discloses a polypeptide for inhibiting aggregation and toxicity of beta amyloid protein (A beta) or a variant of the polypeptide with polypeptide functions. The polypeptide has a strong binding force with the A beta protein, so that the effective content of a beta structure can be greatly reduced when A beta achieves an aggregation balanced state, the secondary structure of A beta in a solution environment can be changed, the content of the beta structure can be greatly reduced, even the beta structure disappears, the toxicity of A beta to SH-SY5Y cells can be remarkably reduced when the concentration of the polypeptide is extremely low, and generation of A beta-induced active oxygen can be greatly inhibited. Therefore, a feasible method is provided to treatment of Alzheimer disease caused by beta amyloid protein, and thought and reference standard can be provided to discovery of polypeptide pilot compounds for treatment of amyloid protein related diseases.

The invention discloses an application of 5,7-dihydroxy-4'-methoxy flavone preparation extracted from snow lotus in preparation of a medicament for treating ischemic stroke. By effectively extracting the 5,7-dihydroxy-4'-methoxy flavone preparation from the snow lotus and establishing an ischemia reperfusion model of a mouse, the influence of acacetin on the infarct volume and the neurologic impairment caused by ischemia reperfusion injury of the mouse is observed. The study carried out by establishing an SH-SY5Y cell OGD model, testing the cell viability and the cell apoptosis, and demonstrating the integral level of the acacetin shows that the acacetin has the effect of significantly reducing the infarct volume, improving the neurologic function score, promoting the cell survival and reducing the cell apoptosis, clarifies that the acacetin has a neurologic protection effect on the cerebral ischemia reperfusion injury and proves that the 5,7-dihydroxy-4'-methoxy flavone preparation can be well applied to preparing the medicament for treating ischemic stroke and has wide application value.

The invention provides a method for preparing recombinant human amyloid protein A Beta42 and application of the recombinant human amyloid protein, which belongs to the technical field of fusion protein. In the method, PCR sense primer P1 of the human amyloid A Beta42 is designed; a BamHI restriction enzyme cutting site, an anti-sense primers P2, a Sall restriction enzyme cutting site and a terminator codon TAG are introduced according to the sequence of the precusor protein APP of the human amyloid and multiple cloning sites of the cloning vector pGEX-4T-1. cDNA of human SH-SY5Y cells is taken as a templet for amplifing PCR; the length of the fragment of the product is 147bp. The Beta42 fragment of human APP from 672 to 713 is encoded. The A Beta42 gene fragment sequence is combined into a prokaryotic expression vector pGEX-4T-1 to form the prokaryotic expression plasmids pGEX-4T-1 / A Beta42 of human A Beta42. PGEX-4T-1 / A Beta42 is transformed into colibacillus BL21 (DE3), and purified activated recombinant human amyloid A Beta42 is got through induced expression, separation and enzyme cutting.

The invention relates to the medical technical field, in particular to a pentacyclic triterpene compound which is separated to be obtained from a ranunculaceae plant of pulsatilla cernua (Thunb.) Bercht.et Opiz, and the chemical structural formula is shown in the accompanying drawing, wherein glc, rha and ara respectively represent beta-D-glucopyranose, alpha-L-pyrane rhamnose and alpha-L-pyrane arabinose, and the compounds A and B are respectively a new compound. Cell experiments in vitro show that the compound has a remarkable protection function to neuroblastoma cell strain SH-SY5Y induced by A beta (25-35). The compound disclosed by the invention has the advantages of simpleness in preparation and remarkable activity. The invention provides the new compound for preventing and curing AD (Alzheimer's Disease). In the invention, the glc, rha and ara respectively represent beta-D-glucopyranose, alpha-L-pyrane rhamnose and alpha-L-pyrane arabinose.

The invention discloses a composition of extractives of hedysarum polysaccharide and rhodiola rosea, a preparation method thereof and application of compatibility of the same in preparing medicines for treating AD. The compatibility of the extractives of hedysarum polysaccharide and rhodiola rosea in the invention can remarkably protect SH-SY5Y cells from being damaged by Abeta25-35 and increase the viability of the SH-SY5Y cells; according to results of Morris water maze tests, it is revealed that the extractives of hedysarum polysaccharide and rhodiola rosea can substantially enhance learning and memory ability and cognitive impairment of AD model rats; according to results of further detection, the compatibility of the extractives of hedysarum polysaccharide and rhodiola rosea enables the level of glucose metabolism in brains of the AD model rats to recover, which indicates that the compatibility of the extractives of hedysarum polysaccharide and rhodiola rosea has the effect of treating AD and has a remarkable effect.

The invention relates to the cell transdifferentiation technology in the field of cell research, in particular to a method for inducing neuroblastoma cells to be differentiated to nerve cells. The neuroblastoma cells are cultured for 3-7 days through an inducing culture medium, and then the nerve cells are obtained; the inducing culture medium is obtained by adding retinoic acid to a neural stem cell condition culture solution to 10 micrometers; a complete culture medium including a DMEM / F12 basic cukture mediam, B27, bFGF, EGF, heparn sodium, L-glutamine and mycillin is used for culturing the neural stem cells, the complete culture medium is replaced by a half after culturing is conducted for three days, and the replaced culture solution is the neural stem cell condition culture solution. By means of the method, the differentiation efficiency is improved, and the maturity of the cells and growth of neural synapses of nerve cells are also improved. The cell apoptosis in SH-SY5Y treated through RA can be inhibited.

A drug screening against Parkinson's Disease and the construction of assessment platform are disclosed. The platform is supported by gene cloning technology and transfer gene technology, in vitro analog affection Baramine neuron can be used to screen provisional compound against Parkinson's Disease and leader compound. It can be used to make research for pharmacological assessment and penetrating mechanism.

The invention discloses four astraisoflavan-7-O-beta-D-glucoside compounds with nerve cell protection activity and a preparation method thereof, and relates to a pharmaceutical compound and a preparation method thereof. Four novel astraisoflavan-7-O-beta-D-glucoside compounds are separated from alfalfa roots. Four novel astraisoflavan-7-O-beta-D-glucoside compounds are separated from alfalfa rootsby an activity tracking technology and then purified. Four novel compounds can prevent the H2O2 induced SH-SY5Y nerve cell damage and well protects the nerve cells. An H2O2 induced SH-SY5Y nerve celldamage model is used to evaluate the nerve cell protection performance of the compounds; a prominent dose-effect relationship is represented, and thus the compounds have a good application prospect in the preparation of drugs for treating neurodegenerative diseases.

The invention discloses a fat-soluble extract of ligularia fischeri and a preparation method and application thereof. The active monomer components of the extract comprise Bakkenolide A, ligularia hodgsonii aldehyde and luteolin, the fat-soluble extract of ligularia fischeri has the effects of inhibiting the proliferation of tumor cells SH-SY5Y and MCF-7, and also has a certain effect of scavenging DPPH free radicals, the application of medicines or health care products for resisting oxidation, delaying aging, improving organism immunity, preventing cancer and the like is provided, the fat-soluble extract of ligularia fischeri can also be used as natural antioxidants, and medicines for diseases such as obesity, hyperlipidemia, hypertension, diabetes, fatty liver, coronary heart disease, sleep apnea syndrome and the like caused by the obesity, and the application of the medicines and health care products related to the diseases are provided.

The invention discloses a novel application of red stilbene and red stilbene polysaccharide in preparing medicament for treatment of Alzheimer disease. Red stibene and red stilbene polysaccharide in the invention can protect SH-SY5Y cells from the damage from A beta 25-35, and increase the viability of SH-SY5Y cells. The Morris water maze test indicates that red stibene and red stilbene polysaccharide can improve the cognitive dysfunction of mice with rapid brain aging and rats injected with A beta and AD in the hippocampus. Further histology detection indicates that red stilbene and red stilbene polysaccharide can increase the contents of center neurotransmitters 5-HT, 5-HIAA, NE and DA in rapid aging mice brain, wherein the neurotransmitters are monoamines.

The invention relates to the field of traditional Chinese medicines, and discloses application of Astragaloside IV in the preparation of medicaments for preventing and treating Alzheimer disease. Tests show that the Astragaloside IV can inhibit the secretion of Abeta proteins and beta-secretases, the enzyme activity of the beta-secretases and the enzyme cutting effect of the beta-secretases in SH-SY5Y-APP695sw cells, thereby inhibiting the accumulation of the Abeta proteins. Meanwhile, tests show that the Astragaloside IV can promote oligomerized Abeta degradation, thereby reducing the toxic effect of the Abeta proteins and achieving the purpose of preventing and treating Alzheimer disease. Thus, the invention provides the application of the Astragaloside IV in the preparation of medicaments for preventing and treating Alzheimer disease.

The invention discloses 2,3,6-trideoxyglycosyl demethylepipodophyllotoxin compound or pharmaceutically acceptable ester thereof. The chemical structural formula of the 2,3,6-trideoxyglycosyl demethylepipodophyllotoxin compound is as shown in the figure I in the specification, wherein R represents C1-C6 alkyl, -OH, -NH2, NO2 and halogen groups. The compound has the advantage of being capable of remarkably improving the cytotoxic activity on human lung cancer cells (A549), human hepatoma cells (HepG2), human cervical cancer cells (HeLa), human neuroblastoma cells (SH-SY5Y) and oral cancer vinblastine-resistant cells (KB-VCR) compared with clinical medication of etoposide and has the potential of being developed into anti-tumor drugs.

The invention relates to the technical field of biomedicine, and provides a new target for resisting entervirus type 71 infection and application. A human neuroblastoma cell (SH-SY5Y) is taken as a target cell, expression of host protein of the target cell is down-regulated by adopting an RNA interference technique to look for a host factor which can effectively inhibit the EV71-infected human neuroblastoma cell (SH-SY5Y), and therefore the function of a central nervous system is protected. Through experiments, it is found that a dynamin 1 (NDM1) plays an important role on the EV71-infected SH-SY5Y, and EV71 infection can be obviously inhibited by down-regulating expression of the DNM1. The invention provides application of the DNM1 in preparation of medicine for preventing or treating the entervirus type 71 infection.

The present invention relates to uses of 5-(3,4-methylenedioxy phenyl)-2E,4E pentadienoic acid propylamine amide in preparation of medicinal compositions for treatment and / or prevention of neuron diseases requiring neuroprotection effects and / or nerve regeneration. The 5-(3,4-methylenedioxy phenyl)-2E,4E pentadienoic acid propylamine amide provides good treatment effects for depressions caused by various causes, provides significant anti-depression activity for a pharmacological depression model, provides a good protection effect for SH-SY5Y cells damaged by glutamic acid, and provides a selective inhibition effect for monoamine oxidase B (MAO-B).

The invention discloses application of protocatechualdehyde to preparation of medicaments for treating human neurodegenerative diseases. The invention first discovers that the protocatechualdehyde has activity of interacting with parkinsonism-related protein DJ-1 and further discovers that the protocatechualdehyde has the effects of resisting oxidative stress, preventing apoptosis of SH-SY5Y neurocyte, induced by the oxidative stress, restricting active oxygen in the neurocyte from generating, and the like through experiments. Proved by experimental results, the effect of the protocatechualdehyde to the neurocyte is mediated by the DJ-1 protein, and the protocatechualdehyde has an exact neuroprotective effect and can be used for preventing or treating the neurodegenerative diseases comprising parkinsonism.

The present invention relates to uses of 5-(3,4-methylenedioxy phenyl)-2E,4E pentadienoic acid propylamine amide in preparation of medicinal compositions for treatment and / or prevention of neuron diseases requiring neuroprotection effects and / or nerve regeneration. The 5-(3,4-methylenedioxy phenyl)-2E,4E pentadienoic acid propylamine amide provides good treatment effects for depressions caused by various causes, provides significant anti-depression activity for a pharmacological depression model, provides a good protection effect for SH-SY5Y cells damaged by glutamic acid, and provides a selective inhibition effect for monoamine oxidase B (MAO-B).

The invention discloses a novel application of red stilbene and red stilbene polysaccharide in preparing medicament for treatment of Alzheimer disease. Red stibene and red stilbene polysaccharide in the invention can protect SH-SY5Y cells from the damage from A beta 25-35, and increase the viability of SH-SY5Y cells. The Morris water maze test indicates that red stibene and red stilbene polysaccharide can improve the cognitive dysfunction of mice with rapid brain aging and rats injected with A beta and AD in the hippocampus. Further histology detection indicates that red stilbene and red stilbene polysaccharide can increase the contents of center neurotransmitters 5-HT, 5-HIAA, NE and DA in rapid aging mice brain, wherein the neurotransmitters are monoamines.

The invention provides a method for inducing SH-SY5Y cells to differentiate into dopaminergic neurons. The method comprises: culturing SH-SY5Y cells in a base culture medium until achieving a certain fusion degree, and digesting to obtain a SH-SY5Y cell suspension; and spreading the SH-SY5Y cell suspension onto a culture dish, and culturing in an induction culture medium to obtain the dopaminergic neurons. According to the present invention, with the method, after the SH-SY5Y cells are cultured with the induction culture medium containing aFGF, TPA, Forskolin, dbcAMP and pramipexole, the cells can be induced into the dopaminergic neurons, and dopamine can be secreted; and under the optimized conditions, the differentiation rate of the dopaminergic neurons is about 15%, the induced DAT positive cells account for 5% of the number of the total cells, the differentiation rate is high, and the differentiation level is high.

The invention relates to the field of traditional Chinese medicine, and discloses the application of baicalin in the preparation of drugs for preventing and treating Alzheimer's disease. Experiments have shown that baicalin can inhibit the secretion of Aβ protein and β-secretase in SH-SY5Y-APP695sw cells, the enzymatic activity of β-secretase and the enzymatic cleavage of β-secretase, thereby inhibiting the accumulation of Aβ protein. Simultaneous tests show that baicalin can improve the learning and memory ability, promote the degradation of oligomerized Aβ, thereby reducing the toxic effect of Aβ protein, and achieve the purpose of preventing and treating Alzheimer's disease. Therefore, the present invention provides baicalin in the preparation of prophylaxis and Application of drugs in the treatment of Alzheimer's disease.

The invention relates to preparation and application of an echinacea extract, in particular to the application of the echinacea extract to the preparation of a drug for preventing and treating senile dementia. The echinacea extract mainly comprises plant polyphenol and chicoric acid, and the content of the plant polyphenol and chicoric acid is not smaller than 60 percent. Experiment research shows that echinacea effective components can prevent A Beta 25-35 from damaging SH-SY5Y cells, improve the survival rate of the SH-SY5Y cells and improve the learning and memory ability of APP / PS1 double transgenic dementia mice. The extract can be used for preventing and treating one or more of alzheimer disease, vascular dementia and mixed dementia of alzheimer disease and vascular dementia.

The invention discloses application of a regallily glycoside A to preparation of an antidepressant drug. A cell model and an animal model are adopted for researching the antidepressant activity of the regallily glycoside A component. Test results show that the regallily glycoside A has good protecting activity on SH-SY5Y cells with damaged corticosterone, and the mechanism of the regallily glycoside A is possibly related to apoptosis of inhibitory neuron cells; the regallily glycoside A can obviously shorten the dead time of rat forced swimming and increase the frequency of open field autokinetic movement. It is shown that the regallily glycoside A has a strong antidepressant effect, which exploits a new field for application of monomer components of lilies and other medicinal materials, and the application prospects are broad.

The invention provides an application of a bitter orange volatile oil extract in preparation of an antidepressant drug. The bitter orange volatile oil extract is extracted from a bitter orange medicinal material, and a main component is limonene. An extraction technology of the bitter orange volatile oil extract comprises steps as follows: the bitter orange medicinal material is taken and soaked for 1-3 h, a steam distillation method is adopted, 6-10 times of water in volume is added for extraction for 5-9 h, and the bitter orange volatile oil extract is obtained. A preferable technology comprises steps as follows: the bitter orange medicinal material is taken and soaked for 3 h, the steam distillation method is adopted, 8 times of water in volume is added for extraction for 7 h, and the bitter orange volatile oil extract is obtained. Multiple preparations can be prepared from the bitter orange volatile oil extract, and the bitter orange volatile oil extract can be applied to development of a clinical new antidepressant drug after addition of pharmaceutically acceptable auxiliary materials and carriers. According to the application of the bitter orange volatile oil extract in preparation of the antidepressant drug, in-vitro pharmacological experiments prove that the bitter orange volatile oil extract has a protection effect on hypoxia-injury SH-SY5Y nerve cells, has a remarkable anti-depression function and lays the foundation for development of the new antidepressant drug.

The invention provides an application of a bitter orange volatile oil extract in preparation of an antidepressant drug. The bitter orange volatile oil extract is extracted from a bitter orange medicinal material, and a main component is limonene. An extraction technology of the bitter orange volatile oil extract comprises steps as follows: the bitter orange medicinal material is taken and soaked for 1-3 h, a steam distillation method is adopted, 6-10 times of water in volume is added for extraction for 5-9 h, and the bitter orange volatile oil extract is obtained. A preferable technology comprises steps as follows: the bitter orange medicinal material is taken and soaked for 3 h, the steam distillation method is adopted, 8 times of water in volume is added for extraction for 7 h, and the bitter orange volatile oil extract is obtained. Multiple preparations can be prepared from the bitter orange volatile oil extract, and the bitter orange volatile oil extract can be applied to development of a clinical new antidepressant drug after addition of pharmaceutically acceptable auxiliary materials and carriers. According to the application of the bitter orange volatile oil extract in preparation of the antidepressant drug, in-vitro pharmacological experiments prove that the bitter orange volatile oil extract has a protection effect on hypoxia-injury SH-SY5Y nerve cells, has a remarkable anti-depression function and lays the foundation for development of the new antidepressant drug.

The invention belongs to the technical field of biomedicine, and relates to a novel target used for preventing enterovirus 71 infection, and applications thereof. According to the invention, SH-SY5Y is taken as the target cell, and RNA interference technology is adopted for down-regulation of expression of target cell host protein so as to search host factors capable of inhibiting EV71 infection of SH-SY5Y cells effectively and protect the functions of central nervous systems. It is fond by experiments that calcium-and inte-grin-binding protein, CIB1 molecular possesses significant importance in EV71 infection of SH-SY5Y, and down-regulation of expression of CIB1 is capable of inhibiting EV71 infection obviously. The invention also provides applications of CIB1 in preparing drugs used for preventing or treating EV71 infection.

The invention relates to an extraction method of an antioxidant and an application in protection of nerve cells against oxidation by utilizing the antioxidant, belonging to the technical field of biological medicines. The extraction method disclosed by the invention comprises the following steps of: taking myricaria laxiflora as a raw material, taking ethanol as an extraction solvent, performing Soxhlet extraction, performing cold leaching on a crude extraction solution with HCl, adjusting the pH with saturated NaCO3, extracting with chloroform, performing chloroform-methanol gradient elution by silica gel column chromatography, performing Sephadex LH-20 gel column methanol elution, and further performing crystallization and re-crystallization to obtain the antioxidant. The antioxidant is identified as 3, 4-dimethoxy-5-methylparaben by 1H-NMR and 13C-NMR, the molecular formula is C10H12O5, and the anti-oxidation property and the free radical scavenging activity are stronger. The concentration of the antioxidant is 0.5-12.5mu g / mL, when the dosage is 100mu L, the toxicity of the natural antioxidant against SH-SY5Y cells is less than 3.4%, the relative survival rate against human neuroblastoma cells SH-SY5Y after oxidative damages by hydrogen peroxide is 50-80%, and the antioxidant has a better anti-oxidation protection effect in comparison with PG (propyl gallate), can be used as a natural non-toxic antioxidant and can be applied to the fields of foods, medicines, cosmetics and the like.

The invention relates to an extraction method for (22trans)-3beta-hydroxy-cholest-5,22-diene-24-one in Caulerpa racemosa. According to the present invention, the compound is obtained from Caulerpa racemosa by adopting extracting, pressure reducing concentrating, extracting, and silica gel column chromatography and gel column chromatography purification, the structure of the compound is determined through physicochemical constant determination and spectrum data analysis, and results of a plurality of in vitro nerve protection effect experiments of SH-SY5Y cell damage prove that the compound provides the significant protection effect on the beta-amyloid 25-35(A[beta]25-35) damaged SH-SY5Y cells, and can be used for preparation of nerve protection agents and Alzheimer's disease preventing drugs.

The invention discloses a method for constructing neurons with spontaneous KSHV (Kaposi's Sarcoma-Associated Herpesvirus) lytic replication. The method comprises the following steps: extracting an rKSHV.219 virus with GFP and RFP fluorescent labels from a Vero219 cell, infecting with an SH-SY5Y cell, sorting cells with red fluorescence, and detecting the cell proliferation by cell counting; extracting DNA and RNA in the cells and virus DNA in cell supernatant; detecting the copy numbers of the KSHV in cells and the supernatant, and analyzing the mRNA expression levels of latent-state LANA andlytic-state ORF26; resuscitating after refrigerating the cells for one month, detecting the cell proliferation ability once again, dyeing the freshly-sorted and resuscitated SK-RG cells after being refrigerated, and comparing the changes of eFlour670 attenuation and infection fluorescence signals. The cell proliferation ability is detected, and the change of a clone fluorescence signal formed by SK-RG is detected.

The invention discloses a method for improving the protective effect of creatine on excitatory neurotoxicity, and establishes an exogenous nitric oxide donor GSNO to treat an excitatory neurotoxicitymodel of SH-SY5Y cells. It is proved that a simple creatine factor has the protective effect on the excitatory neurotoxicity by utilizing the model, but the effect is limited. In the SH-SY5Y model treated by the GSNO, both nerve type creatine kinases CKBB and CKMT are modified by nitrosation, and the protein content and enzyme activity are significantly decreased after modification; the nitrosylated modification enzyme GSNOR is removed through overexpression, the nitrosylated modification of the CKBB and CKMT can be significantly reduced, and the content and activity of CKBB and CKMT can be removably restored. By combining the method with the nitrosylated modification removing scheme of the nerve type creatine kinases, the protective effect of creatine on excitatory neurotoxicity can be removably improved.